S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 11.07 CNY 1.84% Market Closed
Market Cap: 13.8B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Cash Paid for Dividends
-ÂĄ308.5m
CAGR 3-Years
11%
CAGR 5-Years
5%
CAGR 10-Years
-2%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash Paid for Dividends
-ÂĄ652.1m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash Paid for Dividends
-ÂĄ2.2B
CAGR 3-Years
-57%
CAGR 5-Years
-41%
CAGR 10-Years
-28%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash Paid for Dividends
-ÂĄ1.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash Paid for Dividends
-ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
-10%
CAGR 10-Years
-22%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash Paid for Dividends
-ÂĄ18.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.8B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.97 CNY
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-308.5m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash Paid for Dividends amounts to -308.5m CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-2%

Over the last year, the Cash Paid for Dividends growth was -6%. The average annual Cash Paid for Dividends growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been 11% over the past three years , 5% over the past five years , and -2% over the past ten years .

Back to Top